The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels ...

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

COVID-19 vaccine recommendations could be changing ... Forshee said one of the study’s limitations includes a “potential selection bias” for patients with more severe cases of myocarditis ...

The Food and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, but with notable ...

Federal health agencies were alerted in February 2021 to "large reports of myocarditis" in young people who received the ...

See what infectious disease doctors have to say as government officials appear poised to scale back COVID vaccines and the ...

The mRNA vaccines were developed using novel technology that was approved for the first time for public use during the COVID-19 pandemic.

An FDA committee on Thursday recommended that COVID-19 vaccines for the 2025-2026 respiratory virus season — which, for the ...

The U.S. FDA has approved Novavax's COVID-19 vaccine, Nuvaxovid, for older adults and those aged 12 to 64 at risk of severe illness. Despite missed deadlines and regulatory challenges, the approval is ...